Positive News Sentiment NASDAQ:EIGR Eiger BioPharmaceuticals - EIGR Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Eiger BioPharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.40 +0.03 (+2.19%) (As of 01/26/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.39▼$1.4850-Day Range$1.02▼$4.5452-Week Range$0.96▼$10.02Volume601,858 shsAverage Volume591,398 shsMarket Capitalization$61.70 millionP/E RatioN/ADividend YieldN/APrice Target$5.33 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability Eiger BioPharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside281.0% Upside$5.33 Price TargetShort InterestHealthy2.72% of Shares Sold ShortDividend StrengthN/ASustainability-1.65Upright™ Environmental ScoreNews Sentiment1.62Based on 3 Articles This WeekInsider TradingAcquiring Shares$71,500 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.28) to ($1.45) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.87 out of 5 starsMedical Sector185th out of 1,048 stocksBiological Products, Except Diagnostic Industry28th out of 168 stocks 3.5 Analyst's Opinion Consensus RatingEiger BioPharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.33, Eiger BioPharmaceuticals has a forecasted upside of 281.0% from its current price of $1.40.Amount of Analyst CoverageEiger BioPharmaceuticals has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.72% of the outstanding shares of Eiger BioPharmaceuticals have been sold short.Short Interest Ratio / Days to CoverEiger BioPharmaceuticals has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eiger BioPharmaceuticals has recently decreased by 21.05%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEiger BioPharmaceuticals does not currently pay a dividend.Dividend GrowthEiger BioPharmaceuticals does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEiger BioPharmaceuticals has received a 61.42% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Lonafarnib" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Eiger BioPharmaceuticals is -1.65. Previous Next 3.1 News and Social Media Coverage News SentimentEiger BioPharmaceuticals has a news sentiment score of 1.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Eiger BioPharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 23 people have searched for EIGR on MarketBeat in the last 30 days. This is a decrease of -34% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Eiger BioPharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Eiger BioPharmaceuticals insiders have bought 171.60% more of their company's stock than they have sold. Specifically, they have bought $71,500.00 in company stock and sold $26,325.00 in company stock.Percentage Held by InsidersOnly 7.40% of the stock of Eiger BioPharmaceuticals is held by insiders.Percentage Held by Institutions69.08% of the stock of Eiger BioPharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Eiger BioPharmaceuticals are expected to grow in the coming year, from ($2.28) to ($1.45) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eiger BioPharmaceuticals is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eiger BioPharmaceuticals is -0.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEiger BioPharmaceuticals has a P/B Ratio of 0.66. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Eiger BioPharmaceuticals (NASDAQ:EIGR) StockEiger BioPharmaceuticals, Inc. engages in the development and commercialization of foundational therapies for Hepatitis Delta Virus. It is also developing avexitide as a treatment for Post-Bariatric Hypoglycemia. The company was founded by David A. Cory and Glenn S. Jeffrey on November 6, 2008 and is headquartered in Palo Alto, CA.Read More Receive EIGR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eiger BioPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address EIGR Stock News HeadlinesJanuary 9, 2023 | benzinga.comFINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Eiger BioPharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmJanuary 6, 2023 | benzinga.comCLASS ACTION UPDATE for EIGR, SGLY and SUNL: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of ShareholdersJanuary 27, 2023 | UNKNOWN (Ad)Become an Investor in Brooklyn GinAward winning super-premium craft gin and upcoming Brooklyn distilleryJanuary 6, 2023 | technews.tmcnet.comThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Eiger BioPharmaceuticals, Inc. (EIGR)January 5, 2023 | benzinga.comCLASS ACTION UPDATE for EIGR, AFRM and SGLY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of ShareholdersJanuary 5, 2023 | wsj.comMONDAY DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Eiger BioPharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmJanuary 4, 2023 | benzinga.comEiger BioPharmaceuticals Class Action Deadline: Submit Your Losses to Johnson FistelJanuary 3, 2023 | msn.comLooking Into Eiger BioPharmaceuticals's Recent Short InterestJanuary 27, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…January 2, 2023 | wsj.com7-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Eiger BioPharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmDecember 29, 2022 | finance.yahoo.comThe Scientific Founder & Independent Director of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), Jeffrey Glenn, Just Bought 43% More SharesDecember 20, 2022 | finance.yahoo.comNewsflash: Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Analysts Have Been Trimming Their Revenue ForecastsDecember 19, 2022 | benzinga.comRM LAW Announces Class Action Lawsuit Against Eiger Biopharmaceuticals, Inc.December 15, 2022 | finance.yahoo.comEiger BioPharmaceuticals Announces Leadership ChangeDecember 14, 2022 | markets.businessinsider.comDEADLINE ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 9, 2023 in Eiger Lawsuit - EIGRDecember 12, 2022 | apnews.comEiger Biopharmaceuticals, Inc. (EIGR) Stockholder News: Lead Plaintiff Deadline is Fast Approaching; Contact Robbins LLP for More InformationDecember 12, 2022 | businesswire.comROSEN, TOP RANKED GLOBAL INVESTOR COUNSEL, Encourages Eiger BioPharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – EIGRDecember 9, 2022 | msn.comHow Is The Market Feeling About Eiger BioPharmaceuticals?December 8, 2022 | seekingalpha.comEiger plunges 70% after late-stage data for chronic hepatitis candidateDecember 8, 2022 | msn.comEiger BioPharmaceuticals' Debt OverviewDecember 8, 2022 | finance.yahoo.comEiger Announces Both Lonafarnib-based Treatments in Pivotal Phase 3 D-LIVR Trial in Hepatitis Delta Virus (HDV) Achieved Statistical Significance Against Placebo in Composite Primary EndpointDecember 7, 2022 | benzinga.comCLASS ACTION UPDATE for CMP, EIGR and TSP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of ShareholdersDecember 7, 2022 | finance.yahoo.comEiger BioPharmaceuticals to Host Conference Call to Discuss Phase 3 D-LIVR Study Results of Lonafarnib-based Treatments in Hepatitis Delta Virus (HDV) on Thursday, December 8, 2022December 5, 2022 | benzinga.comINVESTOR ALERT: Edelson Lechtzin LLP is Investigating Securities Fraud Claims on Behalf of Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) ShareholdersDecember 5, 2022 | benzinga.comEiger BioPharmaceuticals Class Action Deadline Alert: Johnson Fistel Encourages Shareholders to Submit Their EIGR LossesDecember 3, 2022 | benzinga.comEIGR LAWSUIT ALERT: Levi & Korsinsky Notifies Eiger BioPharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineDecember 2, 2022 | wsj.comINVESTOR ACTION REMINDER: The Schall Law Firm Encourages Investors in Eiger BioPharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive EIGR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eiger BioPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address EIGR Company Calendar Last Earnings11/03/2022Today1/26/2023Next Earnings (Estimated)3/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EIGR CUSIPN/A CIK1305253 Webwww.eigerbio.com Phone(650) 272-6138Fax650-618-1621Employees43Year FoundedN/APrice Target and Rating Average Stock Price Forecast$5.33 High Stock Price Forecast$9.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+281.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-33,920,000.00 Net Margins-660.21% Pretax Margin-659.90% Return on Equity-106.48% Return on Assets-63.63% Debt Debt-to-Equity Ratio0.50 Current Ratio5.45 Quick Ratio5.34 Sales & Book Value Annual Sales$12.14 million Price / Sales5.08 Cash FlowN/A Price / Cash FlowN/A Book Value$2.13 per share Price / Book0.66Miscellaneous Outstanding Shares44,074,000Free Float40,813,000Market Cap$61.70 million OptionableNot Optionable Beta1.64 Key ExecutivesDavid ApelianChief Executive Officer & DirectorSriram RyaliChief Financial OfficerIngrid C. ChoongSenior Vice President-Clinical DevelopmentChristopher KurtzChief Technical OfficerColin HislopSenior VP-Clinical & Development OperationsKey CompetitorsJounce TherapeuticsNASDAQ:JNCEMiromatrix MedicalNASDAQ:MIROCognition TherapeuticsNASDAQ:CGTXSurface OncologyNASDAQ:SURFAptose BiosciencesNASDAQ:APTOView All CompetitorsInsiders & InstitutionsSigma Planning CorpBought 52,350 shares on 1/24/2023Ownership: 0.264%Thomas John DietzBought 50,000 shares on 1/23/2023Total: $71,500.00 ($1.43/share)DAVENPORT & Co LLCSold 16,900 shares on 1/20/2023Ownership: 0.535%Assenagon Asset Management S.A.Bought 18,388 shares on 1/12/2023Ownership: 1.436%Thomas John DietzSold 22,500 sharesTotal: $26,325.00 ($1.17/share)View All Insider TransactionsView All Institutional Transactions EIGR Stock - Frequently Asked Questions Should I buy or sell Eiger BioPharmaceuticals stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eiger BioPharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EIGR shares. View EIGR analyst ratings or view top-rated stocks. What is Eiger BioPharmaceuticals' stock price forecast for 2023? 1 Wall Street research analysts have issued twelve-month price targets for Eiger BioPharmaceuticals' stock. Their EIGR share price forecasts range from $3.00 to $9.00. On average, they predict the company's share price to reach $5.33 in the next year. This suggests a possible upside of 281.0% from the stock's current price. View analysts price targets for EIGR or view top-rated stocks among Wall Street analysts. How have EIGR shares performed in 2023? Eiger BioPharmaceuticals' stock was trading at $1.18 at the beginning of 2023. Since then, EIGR shares have increased by 18.6% and is now trading at $1.40. View the best growth stocks for 2023 here. Are investors shorting Eiger BioPharmaceuticals? Eiger BioPharmaceuticals saw a drop in short interest in the month of January. As of January 15th, there was short interest totaling 1,200,000 shares, a drop of 21.1% from the December 31st total of 1,520,000 shares. Based on an average trading volume of 905,700 shares, the days-to-cover ratio is currently 1.3 days. View Eiger BioPharmaceuticals' Short Interest. When is Eiger BioPharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023. View our EIGR earnings forecast. How were Eiger BioPharmaceuticals' earnings last quarter? Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) posted its quarterly earnings results on Thursday, November, 3rd. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by $0.07. The biotechnology company earned $4.02 million during the quarter, compared to analyst estimates of $3.93 million. Eiger BioPharmaceuticals had a negative trailing twelve-month return on equity of 106.48% and a negative net margin of 660.21%. What other stocks do shareholders of Eiger BioPharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Eiger BioPharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Gilead Sciences (GILD), Skyworks Solutions (SWKS), ZIOPHARM Oncology (ZIOP), Amarin (AMRN), Celldex Therapeutics (CLDX), Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL), SCYNEXIS (SCYX) and Sangamo Therapeutics (SGMO). What is Eiger BioPharmaceuticals' stock symbol? Eiger BioPharmaceuticals trades on the NASDAQ under the ticker symbol "EIGR." Who are Eiger BioPharmaceuticals' major shareholders? Eiger BioPharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Assenagon Asset Management S.A. (1.44%), DAVENPORT & Co LLC (0.53%) and Sigma Planning Corp (0.26%). Insiders that own company stock include David Apelian, Eldon C Mayer III, Evan Loh, Jeffrey S Glenn, Sriram Ryali and Thomas John Dietz. View institutional ownership trends. How do I buy shares of Eiger BioPharmaceuticals? Shares of EIGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Eiger BioPharmaceuticals' stock price today? One share of EIGR stock can currently be purchased for approximately $1.40. How much money does Eiger BioPharmaceuticals make? Eiger BioPharmaceuticals (NASDAQ:EIGR) has a market capitalization of $61.70 million and generates $12.14 million in revenue each year. The biotechnology company earns $-33,920,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. How can I contact Eiger BioPharmaceuticals? Eiger BioPharmaceuticals' mailing address is 2155 PARK BOULEVARD, PALO ALTO CA, 94306. The official website for the company is www.eigerbio.com. The biotechnology company can be reached via phone at (650) 272-6138, via email at ichoong@eigerbio.com, or via fax at 650-618-1621. This page (NASDAQ:EIGR) was last updated on 1/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.